0
0 (0%)
Larimar Therapeutics, Inc. [ZFGN]
Source:
Company Overview
Larimar Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide ("CPP") technology platform. Our lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name ("INN") and the United States Adopted Name ("USAN") for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich's ataxia (“FA”).
| Country | United States |
| Headquarters | bala cynwyd, pennsylvania |
| Phone Number | (844) 511-9056 |
| Industry | manufacturing |
| CEO | Carole S. Ben-Maimon, M.D. |
| Website | www.larimartx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-90.9 |
| Net Income | $-80.6 |
| Net Cash | $5.7 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -54.4% |
| Profit as % of Stockholder Equity | -46.9% |
Management Effectiveness
| Return on Equity | -46.9% |
| Return on Assets | -40.3% |
| Turnover Ratio | |
| EBITA | $-90.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $200.2 |
| Total Liabilities | $28.4 |
| Operating Cash Flow | $-70.8 |
| Investing Cash Flow | $-85.4 |
| Financing Cash Flow | $161.9 |
